

CLAIMS

1. A pharmaceutical composition comprising at least one carbostyryl derivative in combination with at least one serotonin reuptake inhibitor.
2. The composition of claim 1 wherein the carbostyryl derivative is a dopamine-serotonin system stabilizer.
3. The composition of claim 2 wherein the carbostyryl derivative is aripiprazole.
4. The composition of claim 2 wherein the carbostyryl derivative is a metabolite of aripiprazole.
5. The composition of claim 4 wherein the metabolite of aripiprazole is dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 or DCPP.
6. The composition of any one of claims 1 to 5, wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.
7. The composition of claim 6 wherein at least one serotonin reuptake inhibitor is citalopram.
8. The composition of claim 1, further comprising at least one pharmaceutically acceptable carrier.
9. The composition of any one of claims 1 to 7 being useful for treatment of mood disorders.
10. The composition of claim 9 wherein the mood

disorder is depression or major depressive disorder.

11. The composition of claim 9 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

12. The composition of any one of claims 1 to 7 being useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

13. Use of a pharmaceutical composition comprising at least one carbostyryl derivative in combination with at least one serotonin reuptake inhibitor, in the preparation of a medicament for treating disorders.

14. The use of claim 13 wherein the carbostyryl derivative is a dopamine-serotonin system stabilizer.

15. The use of claim 14 wherein the carbostyryl derivative is aripiprazole.

16. The use of claim 14 wherein the carbostyryl derivative is a metabolite of aripiprazole.

17. The use of claim 16 wherein the metabolite of aripiprazole is dehydroaripiprazole, DM-1458, DM-1451,

DM-1452, DM-1454 or DCPP.

18. The use of any one of claims 13 to 17, wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

19. The use of claim 18 wherein at least one serotonin reuptake inhibitor is citalopram.

20. The use of claim 13 wherein the pharmaceutical composition further comprises at least one pharmaceutically acceptable carrier.

21. The use of any one of claims 13 to 19 wherein the medicament is useful for treatment of mood disorders.

22. The use of claim 21 wherein the mood disorder is depression or major depressive disorder.

23. The use of claim 21 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

24. The use of any one of claims 13 to 19, wherein the medicament is useful for treatment of major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with

depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.

25. A method of treating disorders in a patient comprising administration of an effective amount of a pharmaceutical composition comprising at least one carbostyryl derivative in combination with at least one serotonin reuptake inhibitor.

26. The method of claim 25 wherein the carbostyryl derivative is a dopamine-serotonin system stabilizer.

27. The method of claim 26 wherein the carbostyryl derivative is aripiprazole.

28. The method of claim 26 wherein the carbostyryl derivative is a metabolite of aripiprazole.

29. The method of claim 28 wherein the metabolite of aripiprazole is dehydroaripiprazole, DM-1458, DM-1451, DM-1452, DM-1454 or DCPP.

30. The method of any one of claims 25 to 29, wherein at least one serotonin reuptake inhibitor is selected from the group consisting of fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline, escitalopram and salts thereof.

31. The method of claim 30 wherein at least one serotonin reuptake inhibitor is citalopram.

32. The method of claim 25, wherein the pharmaceutical composition further comprises at least

one pharmaceutically acceptable carrier.

33. The method of any one of claims 25 to 31 wherein the disorders are mood disorders.

34. The method of claim 33 wherein the mood disorder is depression or major depressive disorder.

35. The method of claim 33 wherein the mood disorder is major depressive disorder, all mood disorders, schizoaffective disorder or dementia with depressive symptoms.

36. The method of any one of claims 25 to 31, wherein the disorders are major depressive disorder, endogenous depression, melancholia, depression in combination with psychotic episodes, bipolar disorder with depressive phase, refractory depression, dementia of the Alzheimer's type with depressive symptoms, Parkinson's disease with depressive symptom, senile dementia, mood disorder associated with cerebral blood vessels and mood disorder following head injury.